Application No.: 10/046,278 Attorney Docket No.: 06478.1463-00

**AMENDMENTS TO THE CLAIMS:** 

This listing of claims will replace all prior versions and listings of claims in the

application:

1.-6. (Canceled)

7. (Currently Amended) A method of prophylaxis for a disorder caused

characterized by angiogenesis or arteriogenesis comprising administering active

antithrombin III to a patient in need thereof.

8. (Currently Amended) A method of treating a disorder caused characterized

by angiogenesis or arteriogenesis comprising administering active antithrombin III to a

patient in need thereof.

9. (Previously Presented) The method as claimed in claim 7 or 8, wherein the  $\alpha$ 

isoform of antithrombin III, the  $\beta$  isoform of antithrombin III, a mixture of the two

isoforms, or a concentrate of antithrombin III, is administered.

10. (Currently Amended) The method as claimed in claim 7 or 8, wherein the

disorder is a retinopathy, neuropathy, or an infectious disease such as leprosy.

11. (Previously Presented) The method as claimed in claim 7 or 8, wherein the

disorder is a cancer.

12. (Previously Presented) The method as claimed in claim 11, wherein the

cancer is a cancerous ulcer or a metastasis of cancerous ulcer.

- 2 -

Application No.: 10/046,278 Attorney Docket No.: 06478.1463-00

13. (Previously Presented) The method as claimed in claim 7 or 8, wherein the disorder is rheumatoid arthritis, psoriasis, endometriosis, chronic bronchitis, or a chronic inflammation of the gastrointestinal tract.

- 14. (Previously Presented) The method as claimed in claim 7 or 8, wherein the antithrombin III is prepared recombinantly or transgenically.
- 15. (Previously Presented) The method as claimed in claim 7 or 8, wherein the antithrombin III is administered intravenously, subcutaneously, intramuscularly or topically.
- 16. (New) The method as claimed in claim 10, wherein the infectious disease is leprosy.